Access cutting-edge necrotizing enterocolitis (nec) treatment through this clinical trial at a research site in Salt Lake City. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Salt Lake City location
Preparing your pre-screening questions…
Access necrotizing enterocolitis (nec) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related necrotizing enterocolitis (nec) treatment provided free
Check if you qualify for this necrotizing enterocolitis (nec) clinical trial in Salt Lake City, UT
No-Cost Study Care
Local to Salt Lake City
Convenient for UT residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a prospective in vitro cell biology study of polymorphonuclear leukocyte (PMN) protein synthesis in response to PAF. PMNs from cord blood of premature human infants at risk for NEC (birth weight between 501 - 1500 grams) and PMNs from cord blood of healthy term infants will be isolated and stimulated with PAF, a biologically active phospholipid implicated in the pathogenesis of NEC. NEC, a disease of prematurity with an incidence of 10.1% of infants born weighing between 501 - 1500 grams, is associated with significant morbidity and mortality. We will compare the protein synthesis of inflammatory modulators, including Interleukin 6 Receptor alpha (IL-6R alpha) and Retinoic Acid Receptor alpha (RAR alpha) proteins to protein synthesis responses already observed in PMNs isolated from healthy adults. Furthermore, we will characterize the expression and activity of the mammalian target of rapamycin (mTOR) translational protein synthesis control pathway in PMNs isolated from preterm and term infants and compare those results with previous observations in PMNs isolated from adults. This pathway is known to regulate IL-6R alpha and RAR alpha protein expression in PMNs isolated from adults. We will also follow those premature infants at risk for NEC clinically to determine which infants develop NEC and what risk factors may be associated with NEC in this population.
Sponsor: University of Utah
Yes, this clinical trial (NCT00747851) has an active research site in Salt Lake City, UT that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for necrotizing enterocolitis (nec) treatment options in Salt Lake City, UT, this clinical trial (NCT00747851) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Salt Lake City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced necrotizing enterocolitis (nec) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all necrotizing enterocolitis (nec) clinical trials near you to find additional studies recruiting in your area.
See all ulcerative colitis clinical trials recruiting in Salt Lake City — not just this study.
Browse Ulcerative Colitis Trials in Salt Lake City →